Adaptive Sampling
Getting started guides
:quality(80))
A guide to Adaptive Sampling: targeted sequencing reimagined from Oxford Nanopore
This guide introduces Adaptive Sampling, a unique on-device, real-time targeted sequencing method, providing an enhanced whole-genome view.
Workflow overviews
:quality(80))
Comprehensive characterisation of cancer predisposition genes using the Hereditary Cancer Panel
Discover the Hereditary Cancer Panel workflow and streamline your precision oncology research.
Most viewed
:quality(80))
Comprehensive genomic and epigenomic profiling with the Oxford Nanopore Hereditary Cancer Panel
In this application note, we present the design and performance of the Oxford Nanopore Hereditary Cancer Panel targeting 258 key genes implicated in cancer predisposition.
:quality(80))
Digital Panel Designer
In this flyer, discover how our Digital Panel Designer makes it easy to create, modify, and customise digital panels for Adaptive Sampling sequencing runs.
:quality(80))
Hereditary Cancer Panel: targeted sequencing via adaptive sampling
In this flyer, discover how to utilise the Oxford Nanopore Hereditary Cancer Panel to investigate 258 key genes associated with hereditary cancer risk.
Featured resources
:quality(80))
Real-time targeted sequencing with adaptive sampling | LC 25
AbstractDiscover adaptive sampling: a simple, on-device enrichment method that requires no additional wet-lab prep and offers real-time data analysis for faster access to results.
:quality(80))
Adaptive Sampling enables rapid and complete profiling of pediatric cancers | LC26
Timely and comprehensive molecular classification is essential for therapeutic decision-making in pediatric oncology, yet current diagnostic workflows rely on multi-step, time- and resource-intensive testing. We present a standardized Oxford Nanopore Technologies whole-genome sequencing approach usi
:quality(80))
Building a multiomic homologous recombination deficiency clinical test using Adaptive Sampling | LC26
Homologous recombination deficiency (HRD) affects breast, ovarian, pancreas and prostate cancers. Patients with HRD tumours can respond to poly ADP-ribose polymerase (PARP) inhibitors and platinum-based therapies. HRD results in a variety of single base, insertion and deletion, and large structural
Latest research
:quality(80))
Analysis tools for resolving challenging medically relevant genes using nanopore whole-genome and digital panel data
Analysis tools for resolving challenging medically relevant genes using nanopore whole-genome and digital panel data
:quality(80))
Adaptive sampling explained: the future of flexible target enrichment
Join us for a deep dive into adaptive sampling, a unique software-based target enrichment method from Oxford Nanopore Technologies.
:quality(80))
ROBIN - revolutionising brain tumour classification with real-time Oxford Nanopore sequencing and adaptive sampling
Learn how real-time Oxford Nanopore sequencing results enables rapid methylation classification of tumours.
:quality(80))
Long-read sequencing and adaptive sampling solve complex diagnostic conundrums | LC 25
Prof. Sebastian Lunke is the Head of Division of Genetics and Genomics at the Victorian Clinical Genetics Services. His team oversees the development and delivery of clinically accredited genetics and genomics laboratories in Australia, with a strong focus on translating...
:quality(80))
Variant phasing for antisense oligonucleotide design using adaptive sampling | LC 25
Joy Goffena is a Research Scientist in Dr Danny Miller’s lab at the University of Washington. She specializes in applying Oxford Nanopore Technologies sequencing to advance genetic research and clinical diagnostics. Her work focuses on identifying causal genetic variants...
